International Stem Cell Corp. (ISCO) Study Reveals Promising Developments
International Stem Cell Corp. announced today that behavioral improvements have been observed after six months in their pre-clinical non-human primate (NHP) study of Parkinson's disease (PD). ISCO is a biotechnology company developing novel stem cell-based therapies and biomedical products and is based in Carlsbad, California. The detailed behavioral data is slated to be presented at the 66th American Academy of Neurology Annual Meeting in Philadelphia. "It is encouraging to see these behavioral scores trending in the right direction as it means that the implanted cells may be having a positive impact on the disease symptoms," said Professor D. Eugene Redmond…